Cure8 research brief
Why This Matters
CMV colitis can complicate moderate–severe UC flares and—if present—is associated here with longer hospital stays, more frequent escalation to anti‑TNF therapy, and higher colectomy risk.
Knowing risk factors (prior steroids, PSC, higher disease activity, elevated ESR) can help clinicians consider CMV testing in hospitalized UC patients.
Who Should Pay Attention
Adult patients with moderate–severe ulcerative colitis, clinicians managing hospitalized UC flares, gastroenterology researchers, and patients on or recently exposed to steroids or biologics.
Study Snapshot
What To Know
The paper reports results from a single tertiary center reviewing UC admissions from 2017–2023 where CMV was diagnosed by colonic biopsy with immunohistochemistry. The authors identified steroid exposure, PSC, disease severity (Mayo DAI), and higher ESR as independent risk factors for biopsy-proven CMV colitis in this cohort.
If CMV is detected, the study observed higher downstream use of anti-TNF agents and a higher chance of colectomy, suggesting CMV colitis in hospitalized UC patients is linked to worse short- and mid-term clinical outcomes in this dataset.
Keep In Mind
Findings come from a retrospective cohort at one tertiary hospital (2017–2023) using biopsy/IHC to diagnose CMV; results show associations but not causation. Local practice and patient mix may affect generalizability.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.